Abstract | OBJECTIVE: METHODS: A total of 132 PD patients from China were randomly assigned to receive 20 mg/day istradefylline plus sham-rTMS (Group I), 40 mg/day istradefylline plus sham-rTMS (Group II), placebo plus 1 Hz rTMS (Group III) and placebo plus 10 Hz rTMS (Group IV) for 12 weeks. Unified Parkinson's Disease Rating Scale (UPDRS) part III score was the primary outcome. Clinical Global Impression-Global Improvement (CGI-I) was the secondary outcome. The change in daily off time in Groups I and II was also recorded. RESULTS: After 12 weeks of treatment, the changes in UPDRS part III score were -6.05, -6.39, -5.91 and -6.46 for Groups I, II, III and IV, respectively, and the difference was not significant. The difference in CGI-I among the four groups was not significant. The daily off time was reduced by -1.43 hours in Group I and -1.62 hours in Group II. No severe adverse events occurred among the four groups. CONCLUSION: These results indicate that, as augmentation agents to levodopa in the treatment of PD, istradefylline and rTMS had comparable efficacy and tolerability.
|
Authors | Zhi-jun Li, Qian Wu, Chen-ju Yi |
Journal | Current medical research and opinion
(Curr Med Res Opin)
Vol. 31
Issue 11
Pg. 2055-8
(Nov 2015)
ISSN: 1473-4877 [Electronic] England |
PMID | 26393386
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Purines
- istradefylline
- Levodopa
|
Topics |
- Aged
- China
- Female
- Humans
- Levodopa
(administration & dosage, therapeutic use)
- Male
- Middle Aged
- Parkinson Disease
(drug therapy, therapy)
- Purines
(administration & dosage, therapeutic use)
- Transcranial Magnetic Stimulation
(methods)
- Treatment Outcome
|